CLOs on the Move

Innocrin Pharmaceuticals

www.innocrinpharma.com

 
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Shire

At Shire, we enable people with life altering conditions to lead better lives. We focus on developing and delivering innovative treatments for patients with rare diseases and other specialty conditions.To realize our aspiration to become a leading global biotech, our efforts are concentrated on four key strategic drivers: growth, innovation, efficiency, and people. Our priorities are to drive optimal performance of our existing products, increase patient access to these medicines, and to build our pipeline through research and development and partnerships in order to deliver new medicines to patients.

Greenstone

Greenstone is a Peapack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Wilmington Pharmaceuticals

Wilmington Pharmaceuticals is a Wilmington, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

biopharmservices

biopharmservices is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arjo

We believe that empowering movement within healthcare environments is essential to quality care. ⚖️ https://t.co/e11hfbUA49